The Federal Circuit upheld Judge Zobel 2019s grant of JMOL of non-infringement, agreeing that the evidence presented failed as a matter of law to prove that each limitation of the asserted claims was found in the accused product. The patent covered methods for treatment of episodic heartburn by combining known H2-blockers and known antacids to create a product that provides, as the claims recited, immediate and long-lasting relief from heartburn symptoms. The specification defined 201cimmediate 201d relief as starting within about 5-10 minutes following ingestion. Brigham and Women 2019s sought to prove infringement by looking to the efficacy data for the commercialized Pepcid Complete 00ae product, which the Perrigo generic (having the same active ingredients and dosages) would necessarily match. The clinical data did not, however, match up with the claim limitations 2013 a first test measuring esophageal pH failed to correlate any particular pH change with relief from symptoms, and the two tests that addressed symptomatic relief did not begin measuring relief until 15 minutes had passed. Brigham and Women 2019s had asserted only literal infringement, not infringement by equivalents; accordingly, this difference in time was insufficient to prove the product met the claim limitation. The Court declined to rule on Perrigo 2019s appeal of the denial of JMOL of invalidity, noting that the strong public interest in resolving questions of patentability were absent because the sole patent in suit had had expired in 2012 and there were no related patents in examination and no other lawsuits involving the patent.
By submitting this form, you are consenting to receive marketing emails from: Lando & Anastasi, LLP. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
SHARE THIS POST